Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03027687
Other study ID # NL58190.078.16
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 2016
Est. completion date July 2018

Study information

Verified date November 2018
Source Erasmus Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Bilateral (left cathodal/ right anodal) transcranial Direct Current Stimulation (tDCS) over the dorsolateral prefrontal cortex (DLPFC) seems to reduce craving and to increase the time till smoking the first cigarette after the intervention. The current study explores whether actual cigarette consumption decreases after repetitive tDCS. Cigarette consumption and craving will therefore be measured by means of EMA, before (at baseline), during and after multiple tDCS sessions, and at 3 months follow-up.

To study the working mechanism behind the effects of tDCS, electrophysiological responses (ERPs) and behavioral measures of cognitive control functioning will be taken into account at baseline, one day after the last tDCS session and at three months follow up.

We hypothesize that cigarette consumption will decrease after repetitive tDCS, and that this effect is associated with better cognitive control functioning.


Description:

The proposed experiment is a double-blind randomized placebo-controlled trial. 60 smokers will be randomly assigned to two conditions, namely tDCS or sham (placebo).

Participants will receive real tDCS or sham for three days in one week. The interventions contain twice daily sessions for 13 minutes with an interval of 20 min. Moreover, on the first treatment day and the day after the treatment week, participants complete a number of questionnaires, and perform two psychological tasks (a gambling task and the Go/NoGo task) to measure cognitive control functioning (e.g. risky decision making and inhibitory control respectively). During these tasks, event-related potentials will be recorded by means of EEG. After three months, participants are asked to return to fill out the same questionnaires and perform the same psychological tasks as before, to measure the lasting effect of tDCS. During this last session, event-related potentials will also be recorded. In addition, carbon monoxide levels will be measured on all days where subjects perform the tasks.

EMA:

For three weeks, starting the week before tDCS treatment, participants are asked to log every cigarette before they smoke one. During these weeks, participants complete EMA questionnaires on their mobile phone about cigarette consumption, craving, and affect that will take approximately 5 minutes. The EMA questionnaire will be presented four times daily on a quasi-random basis. Finally, during end-of-day assessments participants have the possibility to indicate any missed cigarettes. At three months follow-up, participants are asked to undergo the same EMA procedure for one more week, to study the lasting effects of tDCS.


Recruitment information / eligibility

Status Completed
Enrollment 73
Est. completion date July 2018
Est. primary completion date March 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Currently smoking 10 or more cigarettes a day

- The ability to speak, read, and write in Dutch at an eight-grade literacy level

Exclusion Criteria:

- The current abuse of a substance other than nicotine or caffeine

- History of neurological or psychiatric disorders

- Any contraindication for electrical brain stimulation procedures such as electronic implants or metal implants

- Pregnancy or breast-feeding

- In the process of quitting smoking

Study Design


Related Conditions & MeSH terms


Intervention

Device:
tDCS
tDCS is an electrical brain stimulation method

Locations

Country Name City State
Netherlands Erasmus University Rotterdam Zuid-Holland

Sponsors (1)

Lead Sponsor Collaborator
Erasmus Medical Center

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean number of cigarettes a day at 3 months follow up The mean number of cigarettes will be measured at three months follow-up by means of Ecological Momentary Assessments (EMA). This means that participants are asked to report every cigarette they smoke at the moment they're about to smoke it with an app on their mobile phone. Participants do this during the week before the last EEG session at three months follow-up.The mean number will be calculated over this week 3 months
Secondary Mean number of cigarettes a day one week after tDCS The mean number of cigarettes will be measured at one week after the last tDCS session by means of Ecological Momentary Assessments (EMA). This means that participants are asked to report every cigarette they smoke at the moment they're about to smoke it with an app on their mobile phone. Participants do this for one week starting from the last tDCS session. The mean number will be calculated over this week 1 week
Secondary Craving at 3 months follow-up Participants receive 4 prompts a day in the app on the smartphone to fill out questions about craving for 1 week starting the week before the last EEG session at three months follow-up 3 months
Secondary Affect 3 months after tDCS Participants receive 4 prompts a day in the app on the smartphone to fill out questions about affect for 1 week starting the week before the last EEG session at three months follow-up 3 months
Secondary Craving one week after tDCS Participants receive 4 prompts a day in the app on the smartphone to fill out questions about craving for 1 week starting the day after the last tDCS session 1 week
Secondary Affect one week after tDCS Participants receive 4 prompts a day in the app on the smartphone to fill out questions about affect for 1 week starting the day after the last tDCS session 1 week
Secondary Behavioral responses of risk-taking Measured with the two-choice gambling task: proportion of high-risk (higher values) choices 3 times: at baseline, one day after all tDCS sessions, and at 3 months follow-up
Secondary Behavioral responses of inhibitory control Measured by proportion correctly inhibited NoGo trials on the Go/NoGo task 3 times: at baseline, one day after all tDCS sessions, and at 3 months follow-up
Secondary Feedback Related Negativity (FRN): Event Related potential (ERP) of reward processing Measured with the two choice gambling task. After the choice (high/low risk) is made, participants receive feedback (either they lose or win). The Feedback Related Negativity (FRN) will be measured after feedback by means of EEG. 3 times: at baseline, one day after all tDCS sessions, and at 3 months follow-up
Secondary Reward related P300: Event related potential (ERP) of reward processing Measured with the two choice gambling task. After the choice (high/low risk) is made, participants receive feedback (either they lose or win). The reward related P300 will be measured 300-500 ms after feedback by means of EEG. 3 times: at baseline, one day after all tDCS sessions, and at 3 months follow-up
Secondary N200: Event related potential (ERP) of inhibitory control The N200 will be measured after NoGo trials in the Go/NoGo task 3 times: at baseline, one day after all tDCS sessions, and at 3 months follow-up
Secondary P300: Event related potential (ERP) of inhibitory control The P300 will be measured after NoGo trials in the Go/NoGo task 3 times: at baseline, one day after all tDCS sessions, and at 3 months follow-up
Secondary Error related negativity: Event related potential (ERP) of error processing Wrong responses to Go and NoGo trials in the Go/NoGo task will be used to assess the error related negativity (ERN) 3 times: at baseline, one day after all tDCS sessions, and at 3 months follow-up
Secondary Course of cigarette consumption Number of cigarettes (and craving) a day starting on the first tDCS day until one week after the last tDCS intervention 2 weeks
See also
  Status Clinical Trial Phase
Terminated NCT03576768 - QuitFast: Evaluating Transcranial Magnetic Stimulation as a Tool to Reduce Smoking Directly Following a Quit Attempt N/A
Completed NCT04110626 - Realistic Evaluation of Expériences Animées, a School-based Intervention in Nouvelle Aquitaine
Completed NCT03007940 - Using NIATx Strategies to Implement Integrated Services in Routine Care N/A
Not yet recruiting NCT04030858 - The INFINITE Study: A Prospective Investigation of a Nutrient-dense Diet in Early Addiction Recovery N/A
Completed NCT03347643 - The Effectiveness of tDCS on Internet Game Addiction Phase 2
Active, not recruiting NCT02836080 - Integrated Collaborative Care Teams for Youth With Mental Health and/or Addiction Challenges (YouthCan IMPACT) N/A
Completed NCT03221985 - ESM Pilot: Mobile Phones and Psychology N/A
Completed NCT02556060 - Lamotrigine for Ketamine Dependence Trial Phase 2/Phase 3
Completed NCT01531153 - Cognitive Enhancement as a Target for Cocaine Pharmacotherapy N/A
Completed NCT02812810 - Evaluation of the Efficacy of Repetitive Transcranial Magnetic Stimulation (rTMS) Low-frequency on Craving in Smoking Dependence N/A
Recruiting NCT05976646 - Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion Phase 1/Phase 2
Completed NCT04409106 - The Turkish Version of the Parental Smartphone Use Management Scale (PSUMS)
Recruiting NCT05595759 - Violence Against Women in Patients With Alcohol Substance Addiction Training N/A
Completed NCT04099173 - A Brief Mindfulness-Based Intervention for Suicidal Ideation N/A
Recruiting NCT04959643 - Systematic Screening for Viral Hepatitis B and C at the PASS Consultation of the Montpellier University Hospital
Completed NCT04133688 - Mobile App in Addiction N/A
Recruiting NCT04063267 - Electronic Cigarettes as a Harm Reduction Strategy in Individuals With Substance Use Disorder Phase 2
Completed NCT05114577 - Recovery Sleepers: A Pilot Study of a Sleep Health Intervention for College Students in Recovery N/A
Terminated NCT02671240 - Prognosis of Behavioral Addiction in Parkinson's Disease
Not yet recruiting NCT03813095 - Exploratory Dose Ranging Study Assessing APH-1501 for the Treatment of Opioid Addiction Phase 2